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Available online 29 June 2013Abstract Anterior foregut endoderm (AFE) gives rise to therapeutically relevant cell types in tissues such as the esophagus,
salivary glands, lung, thymus, parathyroid and thyroid. Despite its importance, reports describing the generation of AFE
from pluripotent stem cells (PSCs) by directed differentiation have mainly focused on the Nkx2.1+ lung and thyroid lineages.
Here, we describe a novel protocol to derive a subdomain of AFE, identified by expression of Pax9, from PSCs using
small molecules and defined media conditions. We generated a reporter PSC line for isolation and characterization of Pax9+
AFE cells, which when transplanted in vivo, can form several distinct complex AFE-derived epithelia, including mucosal
glands and stratified squamous epithelium. Finally, we show that the directed differentiation protocol can be used to generate
AFE from human PSCs. Thus, this work both broadens the range of PSC-derived AFE tissues and creates a platform enabling
the study of AFE disorders.
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http://dx.doi.org/10.1016/j.scr.2013.06.0071. IntroductionThe ability to generate specific tissues from pluripotent
stem cells (PSCs) is an important goal for developing human
cell replacement therapies and to enable the generation of
disease-specific models. While much attention has focused
on the derivation of organs involved in metabolic diseases,
such as the pancreas and liver, fewer studies have addressed
organs derived from anterior foregut endoderm (AFE).
Arising from a regional domain of definitive endoderm
(DE), the AFE contributes to many organs including the
salivary glands, esophagus, stomach, trachea, and lungs. It
1004 N.A. Kearns et al.also gives rise to the pharyngeal endoderm, which in turn
forms the thymus, parathyroid glands, thyroid gland and
ultimobranchial bodies (Zorn & Wells, 2009).
One approach to generate specific cell populations is
to direct PSCs toward a desired cell type by sequential
progression through intermediate cell populations, mimicking
the stages of embryonic development. Monolayer differentia-
tion approaches allow homogeneous accessibility of cells to
exogenous signals required to guide cell fate decisions. Indeed,
monolayer differentiation strategies have been employed
to produce definitive endoderm (DE), the precursor of AFE,
from PSCs through activation of the wingless (WNT) and TGFβ
signaling pathways (Sherwood et al., 2011; D'Amour et al.,
2005). More recently, AFE has been generated from PSC-
derived definitive endoderm (DE) in vitro and upon further
differentiation can be directed to express the lung- and
thyroid-specific transcription factor Nkx2.1 (Mou et al., 2012;
Longmire et al., 2012; Wong et al., 2012; Green et al., 2011).
The generation of organized AFE epithelia has also been
reported, however these are currently limited to respiratory
epithelial lineages (Mou et al., 2012; Wong et al., 2012),
necessitating further work to produce additional organized AFE
epithelia from PSCs. In order to develop a protocol to produce
AFE capable of forming a broader spectrum of AFE-derived
epithelia, we selected the transcription factor Pax9 for use as
an AFE marker based on its broad expression domain (Fig. 1A).
Pax9 is expressed from e9.0 in the developing murine
pharyngeal foregut endoderm and is required for the develop-
ment of the thymus, parathyroid and ultimobranchial bodies
(Peters et al., 1998). Pax9 expression is retained in several
AFE-derived mature cell types including the oral epithelium,
salivary glands, parathyroid gland, thymus, esophagus and
fore-stomach (Peters et al., 1998). Although the generation of
PAX9+ cell containing AFE cultures has been reported from
human PSCs (Green et al., 2011), upon transplantation,
obtained organized epithelial structures expressed genes
indicative of lung epithelial cells rather than other PAX9+ AFE
derived epithelia. Thus, there is a need to explore alternative
approaches to generate PAX9+ cells from PSCs in order to
produce the spectrum of PAX9+ AFE epithelia.
We report a monolayer differentiation approach using small
molecules and chemically definedmedia to generate PAX9+ AFE
cells from bothmouse and human PSCs, thereby minimizing the
contribution of uncharacterized signals during directed differ-
entiation. Through the use of a novel mouse reporter PSC line,
we isolated Pax9+ AFE cells for molecular and functional
characterization. Generated Pax9+ AFE cells not only exhibit
molecular signatures of anterior and pharyngeal foregut
in vitro, but also are competent to form a variety of organized
AFE epithelial structures upon transplantation in vivo. Thus,
these results advance the AFE differentiation field by generat-
ing a transcriptional signature for Pax9+ AFE, broadening the
spectrum of AFE epithelia currently generated from PSCs, and
creating a platform to study AFE developmental disorders.2. Materials and Methods
2.1. Mouse pluripotent stem cell culture
Allmouse PSC lines; AV3, p2lox40, Sox17GFP, and Pax9Venus were
maintained on mouse embryonic fibroblasts (MEF) in KO DMEM(GIBCO, 10829) supplemented with 15% Hyclone FBS (Thermo
Scientific, SH30070.03), 1% Glutamax (GIBCO, 35050079),
1% NEAA (Cellgro, 25-025-CI), 100 μM β-mercaptoethanol
(Invitrogen, 21985023), 1 × 103 units/ml ESGRO LIF (Millipore,
ESG1107). Cells were fed daily and split every 2–3 days with
0.25% trypsin (GIBCO, 25200114).
2.2. Mouse pluripotent stem cell differentiation
Maintenance cultures were split and MEF depleted for
30 min in maintenance media. PSCs were collected and
resuspended in differentiation media 1 [A-DMEM (GIBCO,
12491) supplemented with 1% N2 (GIBCO, 17502-048), 2%
B27 minus vitamin A (GIBCO, 12587-010), 1% Glutamax
(GIBCO, 35050079) 1% P/S (Cellgro, 30-001-CI)] and 10 μM
Y-27632 (Selleck Chemicals, S1049). Cells were plated
at 5 × 103 cells/cm2 onto 0.1% gelatin-coated 6 well plates.
On day 2 cells were fed with differentiation media 1
with 5nM GSK-3 inhibitor XV (Calbiochem, 361558) and
5 μM IDE-1 (Tocris, 4015). On days 3, 4, and 5, cells were
fed with differentiation media 2 [A-DMEM (GIBCO, 12491)
supplemented with 2% B27 minus vitamin A, 1% Glutamax,
1% P/S] plus 5 μM IDE-1. On day 6 cultures were split
with 0.25% trypsin and plated at 3 × 105 cells/cm2 onto
804G conditioned medium-coated plates with 10 μM Y-27632
in differentiation media 2. Cells were treated with 500 nM
A83-01 (Tocris, 2939) and 100 nM LDN193189 (Selleck
Chemicals, S2618).
2.3. Human pluripotent stem cell culture
HUES64 were maintained on mouse embryonic fibroblasts
in KO DMEM (GIBCO, 10829) supplemented with 20% KOSR
(Invitrogen, 10828-028), 1% Glutamax (GIBCO, 35050079),
1% NEAA (Cellgro, 25-025-CI), 55 μM β-mercaptoethanol
(Invitrogen, 21985023), 10 ng/ml bFGF (GIBCO, PH0023).
Cells were fed daily and split every 4–5 days with TrypLE
Express (GIBCO, 12604).
2.4. Human pluripotent stem cell differentiation
Maintenance cultures were split with TrypLE Express and cells
plated at 1–1.5 × 105 cells/cm2 onto growth factor reduced
matrigel (BD Bioscience, 356231)-coated 6well plates in mTESR
(Stem Cell Technologies, 05850). On day 3, cells were fed with
differentiation media [RPMI 1640 (GIBCO, 21870-092) 2% B27
minus vitamin A (GIBCO, 12587-010), 1% Glutamax (GIBCO,
35050079) 1% P/S (Cellgro, 30-001-CI)] supplementedwith 5 nM
GSK-3 inhibitor XV (Calbiochem, 361558) and 5 μM IDE-1
(Tocris, 4015). On days 4–6, cells were fed with differentiation
media supplemented with 5 μM IDE-1. On days 7–13, cells
were fed with differentiation media supplemented with
500 nM A83-01 (Tocris, 2939) and 100 nM LDN193189 (Selleck
Chemicals, S2618).
2.5. Quantitative real time PCR
RNA was isolated using Trizol (Invitrogen, 15596-018) according
to the manufacturer's instructions and 2 μg of RNA was
reverse transcribed to cDNA using SuperScript III (Invitrogen,
Figure 1 A small molecule directed differentiation protocol allows generation of anterior foregut cells from mouse embryonic stem
cells. (A) Schematic of the developing foregut endoderm indicating key transcription factor expression domains (B) Schematic of the
small molecule-directed protocol utilized to generate definitive endoderm and anterior foregut cells from mouse pluripotent stem
cells. Pluripotent stem cells (PSC), definitive endoderm (DE) and anterior foregut (AFE) differentiation stages, small molecules and
timeline are described. (C) Quantitative gene expression analysis of differentiation cultures at day 0 (PSC), day 6 (DE) and day 9
(AFE). Expression levels are expressed relative to PSCs. n = 3 independent experiments ±S.E.M. (D) Representative immunofluorescence
staining of day 6 cultures for SOX17 and FOXA2. (E) Representative immunofluorescence staining of Pax9 + day 9 cultures costained with
EPCAM, SOX2 or FOXA2. Hoechst stain indicates nuclei in blue. Scale bars, 100 μm.
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Master Mix (Applied Biosystems, 4440040) and gene
specific Taqman assays according to the manufacturer'sinstructions (table S2). Relative gene expression was calcu-
lated using the ΔΔCT method; all genes were normalized
to βactin.
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Cells were fixed with 4% paraformaldehyde for 30 min at room
temperature, washed with PBS, washed with PBS + 0.2%
Triton X-100 (PBST), and blocked with 5% donkey serum in
PBST (blocking buffer) for 1 h at room temperature. Primary
antibodies (Table S3) were diluted in blocking buffer at
the indicated concentration and incubated overnight at 4 °C.
Cells were washed three times in PBST, and incubated
with appropriate alexa dye-conjugated secondary antibodies
(Invitrogen) diluted 1:300 in blocking buffer at room temper-
ature for 2 h. Cells were washed three times in PBST. Nuclei
were stained with Hoechst (Invitrogen, H3570). Images were
visualized using a Nikon Ti inverted fluorescence microscope
or a Leica TCS SP5 II confocal microscope.2.7. Flow cytometry and cell sorting
Cells were dissociatedwith 0.25% trypsin and stainedwith a PE/
Cy7 anti-mouse CD326 EpCAM antibody (Biolegend, 118216)
in PBS supplemented with 2% FBS on ice. Flow cytometry
was performed using a Beckman Coulter FC500 flow cytometer
and dead cells excluded with 7AAD (ebioscience, 00-6993-50).
Cell sorting was performed using a Beckman Coulter MoFlo XDP
or BD FACSAria II. All datawas analyzed using FlowJo (Tree Star,
Inc., Ashland, OR).2.8. In vivo maturation assay
1 × 105 sorted VENUS+EPCAM+ cells were resuspended
in 10 μl of recipients' blood and transplanted under the
renal capsule of Nu/Nu mice (Jackson Laboratory). After
4–6 weeks, tissues were fixed in 4% paraformaldehyde for
1–2 h at room temperature and incubated in 30% sucrose
overnight at 4 °C. Tissues were equilibrated in OCT
and then frozen in OCT for cryosectioning. Slides were
immunostained for markers of mature epithelial cell types
(Table S3).Figure 2 Purified Pax9Venus+ anterior foregut cells express a pha
FACS analysis plot of day 0 (PSC), day 6 (DE) and day 9 (AFE) cultures
Dead cells were excluded with 7AAD. n = 3 independent experimen
VENUS+ cells on days 6 and 9 of differentiation with and without T
100 μm. (C) Immunofluorescence of day 9 Pax9Venus+ cultures cost
values (z-scores) for all 2976 differentially expressed genes acr
(3 replicates per cell population) were subjected to hierarchical c
distinct clusters (left). Selected GO terms enriched in individual clu
GO terms see table S1. All gene expression data is available throug
expression levels of selected marker genes across PSC, sorted Sox1
from day 9 (AFE) cultures. Genes are ordered based on marker cl
expression level of all genes for sorted Sox17GFP+ cells from day 6 (DE
Selected marker genes are highlighted in red. (G) Quantitative gen
cultures (n = 3), sorted Pax9VENUS+ EPCAM+ cells from day 9 culture
(n = 1). Expression levels are expressed as fold over PSC expressio
transcripts are indicated.3. Results
3.1. Definitive endoderm cultures generated from
mouse PSCs using small molecules and defined
media differentiate into Pax9 expressing anterior
foregut endoderm
To minimize contribution of undefined signals, we aimed
to develop a novel approach to differentiate DE and
AFE from PSCs using chemically defined media with a B27
supplement and small molecules (Fig. 1B). IDE-1 has
previously been shown to replace the TGFβ agonist Activin
A in PSC differentiation to DE (Borowiak et al., 2009), and
GSK-3 inhibitor XV has been used in place of Wnt3a in
directed differentiation protocols (Sherwood et al., 2011),
however a combinatorial approach of these small molecules
to establish defined media conditions has not been explored.
Following treatment of monolayer PSC cultures with these
molecules, the expression levels of the DE transcription
factors Sox17 and FoxA2 were increased and to a lesser
extent the AFE-specific transcription factors Pax9 and
Pax1 relative to PSCs (Fig. 1C). In concordance, immunoflu-
orescence staining indicated the generation of endodermal
cells coexpressing SOX17 and FOXA2 on day 6 of differenti-
ation (Fig. 1D), demonstrating that PSCs can be differenti-
ated to DE with small molecules in a chemically defined
media.
Previously, Pax9+ AFE has been generated from human
ESC derived DE by inhibition of both the BMP and TGFβ
signaling pathways with Noggin and the small molecule
SB431542, respectively (Green et al., 2011). Based on these
findings, we aimed to generate PAX9+ AFE by treating DE
with the BMP inhibitor LDN193189 (BMPi) and the TGFβ
inhibitor A83-01 (TGFβi) (Fig. 1B). Inclusion of Rock inhibitor
(Y-27632) was used to increase cell survival during plating.
Treating DE cultures with BMPi and TGFβi for 3 days resulted
in decreased expression of Sox17 and FoxA2, and increased
expression of Pax9 and Pax1 relative to DE cultures (Fig. 1C).
Immunofluoresence staining demonstrated that PAX9 cells
generated by this small molecule and defined mediaryngeal foregut gene expression signature. (A) Representative
generated with and without TGFβi/BMPi for VENUS and EPCAM.
ts ±S.E.M. (B) Representative immunofluorescence staining of
GFβi/BMPi. Hoechst stain indicates nuclei in blue. Scale bars,
ained for PAX9. Scale bar, 100 μm. (D) Normalized expression
oss PSC, Sox17GFP+ and Pax9VENUS+ populations. All datasets
lustering (dendrogram top) and k-means clustering for twelve
sters are annotated (right). For a full list of the top 40 enriched
h GEO under accession number GSE42139. (E) Normalized log2
7GFP+ cells from day 6 (DE) cultures and sorted Pax9VENUS+ cells
ass. (F) Scatterplot of the replicate averaged normalized log2
) cultures and sorted Pax9VENUS+ cells from day 9 (AFE) cultures.
e expression analysis of PSCs, sorted Sox17GFP+ cells from day 6
s (n = 3) and sorted Pax9VENUS+ EPCAM+ cells from e9.5 embryos
n. n = 3 independent experiments ±S.E.M. Not detected (n.d.)
1008 N.A. Kearns et al.approach also expressed the AFE markers EPCAM, SOX2 and
FOXA2 (Fig. 1E). To test the hypothesis that the addition of
BMP and TGFβ inhibitors to the cultures is required to
generate AFE from mouse PSCs, we omitted this treatment
from days 6–9. We found that on day 9 of differentiation,
cultures contained PAX9+EPCAM+ cells, and clusters of PAX9
cells also expressed SOX2 and FOXA2, (Fig. S1), leaving open
the possibility that exogenous inhibition of BMP and TGFβ
signaling may not be required under these culture condi-
tions. We conclude that Pax9+ AFE can be produced using a
novel small molecule directed monolayer differentiation
protocol.3.2. Generation of a novel Pax9Venus reporter cell line
enables the isolation and quantification of Pax9+
anterior foregut cells
To enable live cell sorting and quantification of Pax9
expressing cells, we next generated a reporter embryonic
stem cell (ESC) line by targeting the Pax9 locus with a
Venus-containing cassette (Figs. S2A, S2B and S2C). Chimeric
mice generated from this Pax9Venus reporter cell line
expressed VENUS in the pharyngeal endoderm and somites
at e10.5 (Fig. S2D), consistent with the known expression
pattern of Pax9 (Peters et al., 1998). Sagittal sections
through the pharynx of mid-gestation embryos indicate
that VENUS is restricted to PAX9+ cells, and that VENUS
is expressed in a subset of EPCAM+ AFE cells (Figs. S2E
and S2F). To ascertain whether the neomycin resistance
cassette present in the Pax9Venus mice affected the VENUS
expression pattern, we generated Pax9Venus and Pax9VenusΔneo
mice and analyzed VENUS expression at e9.5 (Fig. S3). We
concluded that embryos with and without the neomycin
resistance cassette had comparable VENUS expression pat-
terns at e9.5.
We applied the small molecule and defined media
differentiation protocol to the Pax9Venus reporter cell line
to enable the sorting and quantification of Pax9 expressing
epithelial cells. Only background levels of VENUS expres-
sion were detected in PSC cultures (Fig. 2A). However,
following GSK-3 inhibitor XV and IDE-1 treatment, EPCAM+
cells separated into two distinct cell populations with
VENUS+EPCAM+ cells representing 0.7 ± 0.08% of the culture
(Figs. 2A and B). DE cultures generated with the Pax9Venus
reporter contained 36.2 ± 5.8% SOX17 cells (Fig. S4A). On
day 9 of differentiation, cultures without BMPi and TGFβi
had statistically indistinguishable percentages of VENUS+
cells compared to those treated with BMPi and TGFβi and
during days 6–9 of differentiation (6.8 ± 2.4% and 6.0 ±
1.6% respectively). EpCAM expression on PSCs and DE, as
well as the presence of VENUS-EPCAM+ cells in AFE cultures
precludes the use of EpCAM as a unique marker for isolating
Pax9+ AFE. Cell cultures expanded approximately 20-fold
from PSC to DE and an additional 3-fold from DE to AFE
(Fig. S4B). The VENUS+ cells generated in vitro coexpress
PAX9, supporting the faithfulness of the reporter (Fig. 2C
and Fig. S5A). In conclusion, VENUS+EPCAM+ cells can be
generated using the small molecule and defined media
protocol, enabling both an accurate quantification of Pax9+
AFE cells and the isolation of Pax9+ AFE from in vitro
cultures.3.3. Pax9VENUS+ cells express an anterior foregut
gene expression signature
To gain a more detailed understanding of the molecular
characteristics of our DE and AFE populations, we performed
transcriptional profiling by microarray. To that end, we
purified PSCs, DE, and AFE from our differentiation cultures
through the use of Sox17GFP+ and Pax9Venus reporter cell
lines. We sorted Sox17GFP+EPCAM+ cells from day 6 (DE)
cultures and Pax9VENUS+EPCAM+ cells from day 9 (AFE)
cultures for comparison with MEF-depleted PSCs.
Differential expression analysis identified 2976 genes
differentially expressed at p b 0.001 across the three
populations that clearly separated them from each other
(Fig. 2D). Notably, PSCs clustered separately from Sox17GFP+
DE and Pax9VENUS+ AFE underscoring a higher degree of
similarity between Sox17GFP+ DE and Pax9VENUS+ AFE.
Unsupervised clustering of the differentially expressed
genes revealed 12 distinct expression patterns that include
a gene cluster active in PSC only (enriched for stem cell
maintenance genes p = 9.5 × 10−7), genes upregulated in
Sox17GFP+ DE only (enriched for endoderm developmental
genes, p = 3.1 × 10−8) and an Pax9VENUS+ AFE specific gene
cluster (enriched for genes involved in epithelium develop-
ment, p = 5.5 × 10−7) (Table S1).
As expected, pluripotency markers Pou5f1, Nanog and
Sox2 were highly expressed in PSCs, while Sox17GFP+ DE was
enriched for many known endoderm markers including
Sox17, Mixl1, Cer1, Hhex and FoxA2 (Fig. 2E). Although
Pax9 is expressed in a subdomain of AFE, Pax9 is also
expressed in several other cell lineages (Peters et al., 1998).
Therefore, to determine which population of Pax9+ cells we
had generated in vitro, we examined the expression of key
transcription factors in known Pax9+ lineages. We found that
the Pax9VENUS+ EPCAM+ population expressed higher levels of
the AFE and pharyngeal markers Tbx1, Eya1, Six1, Pax1,
Vgll2, and Rhox4b (Gordon & Manley, 2011; Mielcarek et al.,
2002; Jackson et al., 2003) as compared to PSCs and
Sox17GFP+ DE. In contrast, neither the neuroectoderm and
neural crest markers Sox1, Pax3, Pax6 and Pax7 nor the
somitic transcription factors Pax3, FoxC2 and Mesp2 were
enriched in Pax9VENUS+ EPCAM+ cells.
A detailed comparison of Sox17GFP+ DE and Pax9VENUS+
AFE highlighted 512 genes out of 18,080 as differentially
expressed at p b 0.001. The analysis of differentially
expressed genes highlights a change from Sox17 expression
in Sox17GFP+ DE to Sox2 expression in Pax9VENUS+ AFE
and a concurrent downregulation of early DE markers and
upregulation of regional-specific endoderm markers (Fig. 2F).
To compare the cell populations generated in vitro to
embryonic Pax9VENUS+ EPCAM+ AFE cells, we sorted Pax9VENUS+
EPCAM+ cells from Pax9Venus e9.5 embryos and performed qPCR
analysis (Fig. 2G). We confirmed that ESC-derived Pax9VENUS+
EPCAM+ cells produced in vitro are highly enriched for Pax9,
expressing similar levels to the e9.5 Pax9VENUS+ EPCAM+
embryonic cells. As in the embryo, Tbx1, Pax1, Sox2, Eya1,
Six1 and Vgll2, were all expressed at higher levels
in Pax9VENUS+ EPCAM+AFE than Sox17GFP+ DE, however
expression levels of these genes were higher in the
embryonic e9.5 Pax9VENUS+ EPCAM+ cells than in the
ESC-derived Pax9VENUS+ EPCAM+ cells. FoxA2 expression
levels in in vitro and in vivo Pax9VENUS+ EPCAM+ cells were
Figure 3 Small molecule derived AFE generates stratified squamous epithelia and mucosal epithelia and glands when transplanted
in vivo. (A) Immunofluorescence staining for EPCAM on cryosections of a VENUS+ gland (left) and VENUS+ pseudostratified epithelium
(right). (B) Immunofluorescence staining for PAX9 on cryosections of a VENUS+ pseudostratified epithelium (left) and VENUS+ gland
(right). (C) Hematoxylin and eosin staining of stratified squamous epithelia, indicated by arrow. (D) Identification of a VENUS+
stratified squamous epithelia costained with both KERATIN 14 and KERATIN 8. (E) Hematoxylin and eosin staining of pseudostratified
columnar epithelia, indicated by arrow. (F) Alcian blue staining of pseudostratified columnar epithelia. (G) Mucosal epithelia
analyzed with anti-SOX2 immunofluorescence. (H) Hematoxylin and eosin staining of mucosal gland, indicated by arrow. (I) Alcian
blue staining of a mucosal gland structure. (J) Mucosal epithelia analyzed with anti-MUCIN19 immunofluorescence. Hoechst stain
indicates nuclei in blue. Scale bars, 50 μm.
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SOX2 and FOXA2 by immunofluoresence (Figs. S5B and S5C)
and subsets of VENUS cells expressing TBX1 could be
identified (Fig. S5D). We conclude that Pax9VENUS+ EPCAM+
AFE is distinct from both PSCs and Sox17GFP+ DE, has a
gene expression signature consistent with endodermal
cells found in the developing embryonic Pax9+ anterior
foregut, and does not express markers of alternate Pax9+
lineages.3.4. Upon transplantation, Pax9+ foregut endoderm
can organize into AFE-derived complex epithelial
cell types
To ascertain the differentiation potential of our in vitro
derived AFE, we transplanted sorted Pax9VENUS+ EPCAM+
AFE cells from day 9 directed differentiation cultures under
the kidney capsule of immunocompromised mice. Four
weeks after transplantation the transplants were removed
and several distinct complex epithelial structures express-
ing VENUS were identified. VENUS+ cells retained EPCAM
expression and were part of epithelial structures (Fig. 3A).
VENUS+ cartilage or mesenchyme was not present in the
transplants, reflecting the absence of other non-AFE Pax9+
lineages within the Pax9VENUS+ AFE population. As expected
from the genetic linkage of reporter and Pax9 expression,
VENUS+ epithelia contained PAX9+ cells (Fig. 3B). VENUS+
stratified squamous epithelia were identified in the
transplant (Fig. 3C) consistent with Pax9+ stratified squa-
mous epithelium that develops from the columnar AFE and
lines the pharynx and esophagus (Yu et al., 2005). The
presumptive esophageal endoderm initially expresses ker-
atin 8 (K8) but is replaced with keratin 14 (K14) originating
in the basal layers during stratification (Yu et al., 2005).
Stratified squamous epithelia found in the transplant
expressed K14 in the basal layers, and K8 in the apical cell
layer (Fig. 3D).
VENUS+ pseudostratified columnar epithelium and glan-
dular structures were found in the transplant. These
structures contained cells that stained positive for alcian
blue, indicative of mucosal cells (Figs. 3E, F, H and I) and
SOX2 was expressed in these mucosal epithelial cells
(Fig. 3G). Since Pax9 expression is retained in the mucosal
salivary glands of adult mice (Peters et al., 1998), and the
VENUS+ mucosal glands morphologically resemble the sub-
lingual and minor salivary glands and tracheal submucosal
glands, we stained for salivary mucin 19 (MUC19). MUC19
was detected on the apical surface of VENUS+ mucosal
epithelia (Fig. 3J) consistent with its known expression in
the salivary glands and the tracheal submucosal glands (Das
et al., 2010).
To determine whether any of these VENUS+ epithelia
contained mature 3rd pharyngeal pouch derivatives, we
looked for expression of the parathyroid marker Gcm2, and
the thymus marker FoxN1, but did not detect GCM2 or FOXN1
in the transplants.
We conclude that upon transplantation, VENUS+EPCAM+
AFE generated with small molecules is capable of differenti-
ation and organization into several distinct epithelial types,
including stratified squamous epithelium, pseudostratified
columnar epithelium and mucosal glands.3.5. Pax9+ anterior foregut endoderm can be
produced from human PSCs using small molecules
and defined media
Since many important organs including the thymus, para-
thyroid and thyroid are derived from Pax9+ AFE, protocols to
generate these cells from PSCs would allow the study of
diseases affecting these organs and potentially generate
specific cell types for therapy. To produce Pax9+ AFE from
human PSCs, we adjusted the timing of our small molecule
and defined media directed differentiation protocol (Fig. 4A).
As with mouse PSCs, the human embryonic stem cell line
HUES64 could be differentiated to 48.7 ± 7.8% DE with the
small molecules GSK-3 inhibitor XV and IDE-1 as judged by
coexpression of FOXA2 and SOX17 (Figs. S6A and S6B).
Following the treatment of DE cultures with BMPi and TGFβi,
PAX9 could be detected (Fig. 4B) and PAX9 cells coexpressing
EPCAM, SOX2, FOXA2 and TBX1 and were readily identified
(Fig. 4C). Increases in transcript levels of TBX1, EYA1 and SIX1
relative to day 4 DE cultures were also detected, consistent
with an AFE specification (Fig. S6C). Therefore, Pax9+ AFE can
be generated using small molecule and defined media from
human PSCs.
4. Discussion
The generation of specific AFE-derived cells allow for novel cell
therapies and human disease models for diseases affecting
organs originating from the anterior foregut endoderm. Here,
we report a defined media and small molecule-based differen-
tiation protocol to produce Pax9+ AFE from PSCs that when
matured in vivo are competent to organize into several distinct
types of anterior foregut epithelia. This generation of a
small-molecule directed, defined protocol will be beneficial
for future production of cells for replacement therapies, and to
advance the understanding of the essential signals required
for differentiation. This protocol presents a significant advance
over previous protocols designed to generate PAX9+ AFE, as the
AFE cells generated in this report have the potential to give rise
to multiple AFE-derived organized PAX9+ epithelial structures
including stratified squamous epithelium, pseudostratified
columnar epithelium and mucosal glands.
The use of a novel Pax9Venus reporter PSC line allowed
the purification of PSC-derived Pax9+ AFE for molecular
analysis and enabled the comparison to embryonic Pax9+
AFE. The expression of several pharyngeal endoderm tran-
scription factors in PSC-derived Pax9+ AFE suggests that
these cells may have the capacity to differentiate into
pharyngeal foregut derivatives. Interestingly, expression
levels of several pharyngeal foregut-specific transcription
factors were higher in the embryonic Pax9+ AFE than in
PSC-derived Pax9+ AFE. It is therefore possible that in vitro
Pax9+ AFE represents a more immature cell population and
yet to be identified signals are required to specify pharyngeal
endoderm derived organ domains.
Although we included BMPi and TGFβi in our directed
differentiation protocol, consistent with the published
PAX9+ AFE generating protocol, our data suggests that
these inhibitors may not be required to specify Pax9+ AFE
from DE for mouse PSCs. In concordance, other directed
differentiation protocols did not rely on exogenous BMP
Figure 4 Human pluripotent stem cells can be differentiated to Pax9+ anterior foregut cells using small molecules. (A) Schematic of
the small molecule directed protocol utilized for human pluripotent stem cells (PSCs) to generate definitive endoderm (DE) and
anterior foregut cells (AFE). Differentiation stages, small molecules and time line are described. (B) Quantitative gene expression
analysis of Pax9 in DE and AFE cultures. Expression levels are displayed relative to AFE cells. n = 3 independent experiments ±S.E.M.
Not detected (n.d.) transcripts are indicated. (C) Representative immunofluorescence staining of HUES64 day 9 cultures for PAX9
costained for EPCAM, FOXA2, SOX2 or TBX1. Hoechst stain indicates nuclei in blue. Scale bars, 100 μm.
1011Anterior foregut from PSCs using small moleculesinhibition (Mou et al., 2012) or TGFβ inhibition (Wong et al.,
2012) to generate FOXA2+ SOX2+ AFE cells from PSCs. Thus,
further work is needed to determine the context in which
BMP and TGFβ inhibition are necessary for the generation of
functional Pax9+ AFE.
Importantly, the small molecule and defined media
approach used for mouse PSCs was successfully applied tohuman PSCs, enabling future work to generate human
disease models or to allow the development of novel cell
therapies. Such models could be beneficial to increased
understanding of pharyngeal developmental defects, such as
DiGeorge Syndrome, or Type 1 diabetes, where dysfunction
of pharyngeal endoderm derived-thymic epithelial cells may
contribute to a defective central tolerance induction.
1012 N.A. Kearns et al.5. Conclusions
We utilized small molecules and chemically defined media to
generate PAX9+ AFE cells frommouse and human PSCs. Through
the use of a novel reporter Pax9Venus mouse PSC line, we
isolated PSC-derived PAX9+EPCAM+ cells that had a gene
expression signature consistent with Pax9+ AFE. Upon trans-
plantation in vivo, these cells formed a variety of organized
epithelial structures including Pax9+ stratified squamous
epithelium, pseudostratified columnar epithelium and mucosal
glands. We were able to modify the differentiation protocol for
the human stem cell line HUES64, thereby enabling future work
on human disease modeling and cell replacement therapies.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.06.007.
Acknowledgments
We thank S. Morrison, R. Sherwood and A. McMahon for providing the
Sox17GFP, p2lox40, and AV3 mouse ESC lines, respectively. We thank
L. Atehortua, J. Feng, G. Kenty, L. Paquin, and L. Yagasaki for
technical assistance. We thank the UMass FACS core, confocal core
and transgenic animal modeling core, DERC morphology core and
D. Garlick for assistance with experiments and analysis. We also thank
D. Cohen for critical reading of the manuscript and R. Sherwood
and J. Rajagopal for helpful discussions. We thank D. Melton for initial
financial and logistical support, and for continuing discussions. This
work was supported by The Leona M. and Harry B. Helmsley Charitable
Trust.
References
Borowiak, M., Maehr, R., Chen, S., Chen, A.E., Tang, W., Fox, J.L.,
et al., 2009. Small molecules efficiently direct endodermal
differentiation of mouse and human embryonic stem cells. Cell
Stem Cell 4, 348–358.
D'Amour, K.A., Agulnick, A.D., Eliazer, S., Kelly, O.G., Kroon, E.,
Baetge, E.E., 2005. Efficient differentiation of human embryonicstem cells to definitive endoderm. Nat. Biotechnol. 23,
1534–1541.
Das, B., Cash, M.N., Hand, A.R., Shivazad, A., Grieshaber, S.S.,
Robinson, B., et al., 2010. Tissue distribution of murine Muc19/
Smgc gene products. J. Histochem. Cytochem. 58, 141–156.
Gordon, J., Manley, N.R., 2011. Mechanisms of thymus organogen-
esis and morphogenesis. Development 138, 3865–3878.
Green, M.D., Chen, A., Nostro, M.-C., d'Souza, S.L., Schaniel, C.,
Lemischka, I.R., et al., 2011. Generation of anterior foregut
endoderm from human embryonic and induced pluripotent stem
cells. Nat. Biotechnol. 29, 267–272.
Jackson, M., Baird, J.W., Nichols, J., Wilkie, R., Ansell, J.D.,
Graham, G., et al., 2003. Expression of a novel homeobox gene
Ehox in trophoblast stem cells and pharyngeal pouch endoderm.
Dev. Dyn. 228, 740–744.
Longmire, T.A., Ikonomou, L., Hawkins, F., Christodoulou, C., Cao,
Y., Jean, J.C., et al., 2012. Efficient derivation of purified lung
and thyroid progenitors from embryonic stem cells. Cell Stem
Cell 10, 398–411.
Mielcarek, M., Günther, S., Krüger, M., Braun, T., 2002. VITO-1, a
novel vestigial related protein is predominantly expressed in the
skeletal muscle lineage. Gene Expr. Patterns 2, 305–310.
Mou, H., Zhao, R., Sherwood, R., Ahfeldt, T., Lapey, A., Wain, J., et
al., 2012. Generation of multipotent lung and airway progenitors
from mouse ESCs and patient-specific cystic fibrosis iPSCs. Cell
Stem Cell 10, 385–397.
Peters, H., Neubuser, A., Kratochwil, K., Balling, R., 1998. Pax9-
deficient mice lack pharyngeal pouch derivatives and teeth and
exhibit craniofacial and limb abnormalities. Genes Dev. 12,
2735–2747.
Sherwood, R.I., Maehr, R., Mazzoni, E.O., Melton, D.A., 2011. Wnt
signaling specifies and patterns intestinal endoderm. Mech. Dev.
128, 387–400.
Wong, A.P., Bear, C.E., Chin, S., Pasceri, P., Thompson, T.O., Huan,
L.-J., et al., 2012. Directed differentiation of human pluripotent
stem cells into mature airway epithelia expressing functional
CFTR protein. Nat. Biotechnol. 30 (9), 876–882.
Yu, W.-Y., Slack, J.M.W., Tosh, D., 2005. Conversion of columnar to
stratified squamous epithelium in the developing mouse oesoph-
agus. Dev. Biol. 284, 157–170.
Zorn, A.M., Wells, J.M., 2009. Vertebrate endoderm development
and organ formation. Annu. Rev. Cell Dev. Biol. 25, 221–251.
